Published in Pharm Res on March 03, 2009
Key roles of adjuvants in modern vaccines. Nat Med (2013) 2.62
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol (2012) 1.29
Adjuvants for human vaccines. Curr Opin Immunol (2012) 1.25
Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines (2012) 1.21
Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A (2012) 1.14
Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin Vaccine Immunol (2012) 1.00
Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One (2010) 0.94
Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nat Commun (2015) 0.89
Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict (2013) 0.86
Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. AAPS PharmSciTech (2012) 0.83
Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunol Immunother (2011) 0.82
Vaccine strategies to enhance immune responses in the aged. Curr Opin Immunol (2013) 0.80
Vaccine Potentiation by Combination Adjuvants. Vaccines (Basel) (2014) 0.80
Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant. Hum Vaccin Immunother (2015) 0.78
Phytol-derived novel isoprenoid immunostimulants. Front Immunol (2012) 0.76
Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants. Hum Vaccin Immunother (2015) 0.75
Active Immunization with Extracellular Vesicles Derived from Staphylococcus aureus Effectively Protects against Staphylococcal Lung Infections, Mainly via Th1 Cell-Mediated Immunity. PLoS One (2015) 0.75
Analysis of changing paradigms of management in 179 patients with spinal tuberculosis over a 12-year period and proposal of a new management algorithm. World Neurosurg (2013) 2.94
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine (2011) 2.53
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A (2009) 2.42
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens (2006) 2.09
Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension (2013) 1.76
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol (2008) 1.71
Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood (2007) 1.67
Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology (2008) 1.54
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials (2009) 1.43
Comparative analysis of diagnostic accuracy of different brain biopsy procedures. Neurol India (2006) 1.43
Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J (2009) 1.36
Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol (2005) 1.27
Safety of MF59 adjuvant. Vaccine (2008) 1.25
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine (2007) 1.24
Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol (2009) 1.24
Recent advances in vaccine adjuvants. Pharm Res (2002) 1.22
Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J Infect Dis (2013) 1.16
CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun (2005) 1.16
Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog (2013) 1.15
Endotoxin limits in formulations for preclinical research. J Pharm Sci (2008) 1.12
Recent advances in veterinary vaccine adjuvants. Int J Parasitol (2003) 1.11
Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens (2007) 1.10
The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression. J Exp Med (2014) 1.09
Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol (2009) 1.09
Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release (2005) 1.07
Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS One (2007) 1.06
E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines (2007) 1.05
Microparticle-based technologies for vaccines. Methods (2006) 1.05
Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine (2003) 1.04
Microparticles for the delivery of DNA vaccines. Immunol Rev (2004) 1.04
Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses (2004) 1.04
Phase-sensitive optical coherence elastography at 1.5 million A-Lines per second. Opt Lett (2015) 1.04
Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab (2008) 1.03
Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol (2004) 1.02
Quantitative methods for reconstructing tissue biomechanical properties in optical coherence elastography: a comparison study. Phys Med Biol (2015) 1.00
Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol (2005) 1.00
T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck. Eur J Immunol (2003) 0.99
The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines (2011) 0.98
A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine (2005) 0.97
Spontaneous rupture of hydrocephalic head. Neurol India (2013) 0.96
Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv Drug Deliv Rev (2009) 0.95
The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur J Immunol (2012) 0.95
Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin Vaccine Immunol (2007) 0.95
Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab (2005) 0.94
Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines (2003) 0.94
Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci (2011) 0.94
Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology (2003) 0.94
Spinal teratomas: a clinico-pathological study of 27 patients. Acta Neurochir (Wien) (2009) 0.93
The transcription factor E4BP4 is not required for extramedullary pathways of NK cell development. J Immunol (2014) 0.93
Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas. Neuro Oncol (2013) 0.92
Dynamic optical coherence tomography measurements of elastic wave propagation in tissue-mimicking phantoms and mouse cornea in vivo. J Biomed Opt (2013) 0.92
The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci (2008) 0.92
Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci (2011) 0.92
Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. Eur J Immunol (2006) 0.92
Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs. J Immunol (2007) 0.91
Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol (2006) 0.90
Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol (2006) 0.90
Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood (2009) 0.90
Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interferon Cytokine Res (2015) 0.90
Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv (2006) 0.90
Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res Hum Retroviruses (2006) 0.90
Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol (2003) 0.90
The functional c.-2G>C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels. Hypertension (2010) 0.90
Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides. Proc Natl Acad Sci U S A (2009) 0.89
A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccin (2007) 0.89